Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M7VE
|
|||
| Former ID |
DNCL001800
|
|||
| Drug Name |
RO-4905417
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Acute coronary syndrome [ICD-11: BA41; ICD-9: 411.1] | Phase 2 | [1] | |
| Company |
Roche
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | P-selectin glycoprotein ligand 1 (SELPLG) | Target Info | . | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Staphylococcus aureus infection | ||||
| Pathway Interaction Database | amb2 Integrin signaling | |||
| Reactome | Cell surface interactions at the vascular wall | |||
| WikiPathways | Human Complement System | |||
| Cell surface interactions at the vascular wall | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01245634) A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery. U.S. National Institutes of Health. | |||
| REF 2 | WO patent application no. 2013,0144,05, Methods. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.